Sex-dependent impact of obesity on aggressiveness of papillary thyroid cancer.
Obesity
Papillary thyroid cancer
Risk factors
Sex
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
11
04
2023
accepted:
08
12
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
To investigate the impact of body mass index (BMI) on the aggressiveness of papillary thyroid cancer (PTC). A total of 1720 PTC patients with total thyroidectomy or lobectomy, from January 2017 to April 2020, were retrospectively evaluated. Based on BMI, they were divided into two groups, as follows: control (CON, < 24 kg/m In the whole cohort, the OB group had significantly higher rates of extrathyroidal extension (21.5 vs. 16.8%, p = 0.013), multifocality (43.2 vs. 37.7%, p = 0.018), and BRAF-V600E mutation (82.9 vs. 79.3%, p = 0.015) than the CON group. In males, the OB group had increased rates of tumor size over 1cm (54.4 vs. 42.7%, p = 0.008), extrathyroidal extension (24.9 vs. 12.4%, p = 0.001), and multifocality (42.7 vs. 33.5%, p = 0.038). The OB group had significantly higher adjusted odds ratios (ORs) of 1.63 (1.14-2.33, p = 0.008), 2.12 (1.26-3.57, p = 0.005), and 1.56 (1.07-2.29, p = 0.022) for tumor size over 1cm, extrathyroidal extension, and multifocality compared with CON. Additionally, overweight and obesity were analyzed alone and the rates of extrathyroidal extension (30/100, 30.0%, p = 0.001) and tumor size over 1cm (65/100, 65.0%, p = 0.001) were significantly higher in the obesity group than in the overweight and CON groups. The obesity group had robust higher adjusted ORs of 2.51(1.50-4.20, p < 0.001), 2.93 (1.50-5.73, p = 0.002) and 1.89 (1.11-3.22, p = 0.020) for tumor size over 1cm, extrathyroidal extension, and multifocality compared with CON. Overweight and obesity were predominant independent risk factors for PTC aggressiveness in males. These data indicated that the therapeutic treatment should be based on risk stratification by BMI in males.
Identifiants
pubmed: 38112916
doi: 10.1007/s42000-023-00517-8
pii: 10.1007/s42000-023-00517-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 81902716
Organisme : National Natural Science Foundation of China
ID : 81970677
Organisme : Clinical Research Plan of SHDC
ID : SHDC2020CR6003
Informations de copyright
© 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Références
Lim H, Devesa SS, Sosa JA et al (2017) Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. J Am Med Assoc 317:1338–1348. https://doi.org/10.1001/jama.2017.2719
doi: 10.1001/jama.2017.2719
Li M, Dal Maso L, Vaccarella S (2020) Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol 8:468–470. https://doi.org/10.1016/S2213-8587(20)30115-7
doi: 10.1016/S2213-8587(20)30115-7
pubmed: 32445733
Kitahara CM, Sosa JA (2016) The changing incidence of thyroid cancer. Nat Rev Endocrinol 12:646–653. https://doi.org/10.1038/nrendo.2016.110
doi: 10.1038/nrendo.2016.110
pubmed: 27418023
pmcid: 10311569
Pappa T, Alevizaki M (2014) Obesity and thyroid cancer: a clinical update. Thyroid 24:190–199. https://doi.org/10.1089/thy.2013.0232
doi: 10.1089/thy.2013.0232
pubmed: 23879222
Deng Y, Li H, Wang M et al (2020) Global burden of thyroid cancer from 1990 to 2017. JAMA Netw Open 3:e208759. https://doi.org/10.1001/jamanetworkopen.2020.8759
doi: 10.1001/jamanetworkopen.2020.8759
pubmed: 32589231
pmcid: 7320301
Pan XF, Wang L, Pan A (2021) Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 9:373–392. https://doi.org/10.1016/s2213-8587(21)00045-0
doi: 10.1016/s2213-8587(21)00045-0
pubmed: 34022156
Kwon H, Chang Y, Cho A et al (2019) Metabolic obesity phenotypes and thyroid cancer risk: a cohort study. Thyroid 29:349–358. https://doi.org/10.1089/thy.2018.0327
doi: 10.1089/thy.2018.0327
pubmed: 30648486
Avgerinos KI, Spyrou N, Mantzoros CS et al (2019) Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism: Clin Exp 92:121–35. https://doi.org/10.1016/j.metabol.2018.11.001
doi: 10.1016/j.metabol.2018.11.001
Fussey JM, Beaumont RN, Wood AR et al (2020) Does obesity cause thyroid cancer? A Mendelian randomization study. J Clin Endocrinol Metab 105:e2398–e2407. https://doi.org/10.1210/clinem/dgaa250
doi: 10.1210/clinem/dgaa250
pubmed: 32392279
pmcid: 7274488
Kitahara CM, Pfeiffer RM, Sosa JA et al (2020) Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995–2015). J Natl Cancer Inst 112:810–817. https://doi.org/10.1093/jnci/djz202
doi: 10.1093/jnci/djz202
pubmed: 31638139
Xu L, Port M, Landi S et al (2014) Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid 24:966–974. https://doi.org/10.1089/thy.2013.0566
doi: 10.1089/thy.2013.0566
pubmed: 24555500
pmcid: 4046192
Kim KN, Hwang Y, Kim KH et al (2020) Adolescent overweight and obesity and the risk of papillary thyroid cancer in adulthood: a large-scale case-control study. Sci Rep 10:5000. https://doi.org/10.1038/s41598-020-59245-3
doi: 10.1038/s41598-020-59245-3
pubmed: 32193459
pmcid: 7081310
Li C, Zhou L, Dionigi G et al (2020) The association between tumor tissue calcification, obesity, and thyroid cancer invasiveness in a cohort study. Endocr Pract 26:830–839. https://doi.org/10.4158/EP-2020-0057
doi: 10.4158/EP-2020-0057
pubmed: 33471674
Kaliszewski K, Diakowska D, Rzeszutko M et al (2021) Obesity and overweight are associated with minimal extrathyroidal extension, multifocality and bilaterality of papillary thyroid cancer. J Clin Med 10:970. https://doi.org/10.3390/jcm10050970
doi: 10.3390/jcm10050970
pubmed: 33801171
pmcid: 7957777
Wang H, Wang P, Wu Y et al (2020) Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1579 cases: a retrospective study. PeerJ 8:e9675. https://doi.org/10.7717/peerj.9675
doi: 10.7717/peerj.9675
pubmed: 33194342
pmcid: 7485482
Li CL, Dionigi G, Zhao YS et al (2020) Influence of body mass index on the clinicopathological features of 13,995 papillary thyroid tumors. J Endocrinol Invest 43:1283–1299. https://doi.org/10.1007/s40618-020-01216-6
doi: 10.1007/s40618-020-01216-6
pubmed: 32166701
Zaman SU, Awan MS, Sulaiman MA (2018) Obesity and high risk pathological features of papillary thyroid carcinoma: a retrospective analysis of a university hospital in Pakistan. Gulf J Oncol 1:6–10
Matrone A, Ceccarini G, Beghini M et al (2020) Potential impact of BMI on the aggressiveness of presentation and clinical outcome of differentiated thyroid cancer. J Clin Endocrinol Metab 105:dgz312. https://doi.org/10.1210/clinem/dgz312
doi: 10.1210/clinem/dgz312
pubmed: 31875910
Kim HJ, Kim NK, Choi JH et al (2013) Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol 78:134–140. https://doi.org/10.1111/j.1365-2265.2012.04506.x
doi: 10.1111/j.1365-2265.2012.04506.x
Chen W, Jiang H (2017) Interpretation of the consensus of Chinese experts on nutritional medical treatment for overweight/obesity in 2016. Chin J Pract Intern Med 37:430–3. https://doi.org/10.19538/j.nk2017050117
doi: 10.19538/j.nk2017050117
Huang Y, Qu S, Zhu G et al (2018) BRAF V600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment. J Natl Cancer Inst 110:362–370. https://doi.org/10.1093/jnci/djx227
doi: 10.1093/jnci/djx227
pubmed: 29165667
Collaboration NCDRF (2016) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 387:1377–1396. https://doi.org/10.1016/S0140-6736(16)30054-X
doi: 10.1016/S0140-6736(16)30054-X
Zhao S, Jia X, Fan X et al (2019) Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population: A retrospective case-control study. Medicine (Baltimore) 98:e18213. https://doi.org/10.1097/md.0000000000018213
doi: 10.1097/md.0000000000018213
pubmed: 31852078
Gąsior-Perczak D, Pałyga I, Szymonek M et al (2018) The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer. PLoS ONE 13:e0204668. https://doi.org/10.1371/journal.pone.0204668
doi: 10.1371/journal.pone.0204668
pubmed: 30273371
pmcid: 6166948
Paes JE, Hua K, Nagy R et al (2010) The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab 95:4244–4250. https://doi.org/10.1210/jc.2010-0440
doi: 10.1210/jc.2010-0440
pubmed: 20519347
pmcid: 2936072
Chung YS, Lee JH, Lee YD (2017) Is body mass index relevant to prognosis of papillary thyroid carcinoma? A clinicopathological cohort study. Surg Today 47:506–512. https://doi.org/10.1007/s00595-016-1417-2
doi: 10.1007/s00595-016-1417-2
pubmed: 27654453
Kim SH, Park HS, Kim KH et al (2015) Correlation between obesity and clinicopathological factors in patients with papillary thyroid cancer. Surg Today 45:723–729. https://doi.org/10.1007/s00595-014-0984-3
doi: 10.1007/s00595-014-0984-3
pubmed: 25059345
Feng JW, Yang XH, Wu BQ et al (2019) Influence of body mass index on the clinicopathologic features of papillary thyroid carcinoma. Ann Otol Rhinol Laryngol 128:625–632. https://doi.org/10.1177/0003489419834314
doi: 10.1177/0003489419834314
pubmed: 30841713
Economides A, Giannakou K, Mamais I et al (2021) Association between aggressive clinicopathologic features of papillary thyroid carcinoma and body mass index: a systematic review and meta-analysis. Front Endocrinol 12:692879. https://doi.org/10.3389/fendo.2021.692879
doi: 10.3389/fendo.2021.692879
Cui N, Sun Q, Chen L (2021) A meta-analysis of the influence of body mass index on the clinicopathologic progression of papillary thyroid carcinoma. Medicine (Baltimore) 100:e26882. https://doi.org/10.1097/md.0000000000026882
doi: 10.1097/md.0000000000026882
pubmed: 34397906
Trésallet C, Seman M, Tissier F et al (2014) The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices. Surgery 156:1145–1152. https://doi.org/10.1016/j.surg.2014.04.020
doi: 10.1016/j.surg.2014.04.020
pubmed: 24878452
Derwahl M, Nicula D (2014) Estrogen and its role in thyroid cancer. Endocr Relat Cancer 21:T273–T283. https://doi.org/10.1530/ERC-14-0053
doi: 10.1530/ERC-14-0053
pubmed: 25052473
Du FM, Kuang HY, Duan BH et al (2019) Effects of thyroid hormone and depression on common components of central obesity. J Int Med Res 47:3040–3049. https://doi.org/10.1177/0300060519851624
doi: 10.1177/0300060519851624
pubmed: 31144547
pmcid: 6683926
Celano M, Maggisano V, Lepore SM et al (2019) Expression of leptin receptor and effects of leptin on papillary thyroid carcinoma cells. Int J Endocrinol 2019:5031696. https://doi.org/10.1155/2019/5031696
doi: 10.1155/2019/5031696
pubmed: 30906321
pmcid: 6393892
Mele C, Sama MT, Bisoffi AA et al (2019) Circulating adipokines and metabolic setting in differentiated thyroid cancer. Endocr Connect 8:997–1006. https://doi.org/10.1530/EC-19-0262
doi: 10.1530/EC-19-0262
pubmed: 31252407
pmcid: 6652238
Iyengar NM, Gucalp A, Dannenberg AJ et al (2016) Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol 34:4270–4276. https://doi.org/10.1200/JCO.2016.67.4283
doi: 10.1200/JCO.2016.67.4283
pubmed: 27903155
pmcid: 5562428
Sabharwal SS, Schumacker PT (2014) Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer 14:709–721. https://doi.org/10.1038/nrc3803
doi: 10.1038/nrc3803
pubmed: 25342630
pmcid: 4657553
Yin DT, He H, Yu K et al (2018) The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: A systematic review and meta-analysis. Int J Surg (London, England) 57:66–75. https://doi.org/10.1016/j.ijsu.2018.07.013
doi: 10.1016/j.ijsu.2018.07.013
Tsumagari K, AbdElmageed ZY, Sholl AB et al (2015) Simultaneous suppression of the MAP kinase and NF-kappaB pathways provides a robust therapeutic potential for thyroid cancer. Cancer Lett 368:46–53. https://doi.org/10.1016/j.canlet.2015.07.011
doi: 10.1016/j.canlet.2015.07.011
pubmed: 26208433
pmcid: 4555189
Ma M, Wang M, Zhang Z et al (2021) Apolipoprotein A1 is negatively associated with male papillary thyroid cancer patients: a cross-sectional study of single academic center in China. BMC Endocr Disord 21:69. https://doi.org/10.1186/s12902-021-00714-9
doi: 10.1186/s12902-021-00714-9
pubmed: 33853556
pmcid: 8048163
Yang S, Gong Z, Liu Z et al (2021) Differential effects of estrogen receptor alpha and beta on endogenous ligands of peroxisome proliferator-activated receptor gamma in papillary thyroid cancer. Front Endocrinol 12:708248. https://doi.org/10.3389/fendo.2021.708248
doi: 10.3389/fendo.2021.708248
Park JH, Choi M, Kim JH et al (2020) Metabolic syndrome and the risk of thyroid cancer: a nationwide population-based cohort study. Thyroid 30:1496–1504. https://doi.org/10.1089/thy.2019.0699
doi: 10.1089/thy.2019.0699
pubmed: 32524894
Pinnick KE, Nicholson G, Manolopoulos KN et al (2014) Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 63:3785–3797. https://doi.org/10.2337/db14-0385
doi: 10.2337/db14-0385
pubmed: 24947352